What are the National Comprehensive Cancer Network (NCCN) guidelines for serous carcinoma of the female pelvis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines for serous carcinoma in the female pelvis recommend comprehensive surgical staging, including total hysterectomy, bilateral salpingo-oophorectomy (TH/BSO), and surgical staging, as the initial approach, with chemotherapy being the primary treatment for stages IB, II, III, and IV, as indicated in the guidelines 1.

Key Recommendations

  • The guidelines suggest that the degree of surgical staging to assess disease status depends on intraoperative findings, and multidisciplinary expertise is recommended 1.
  • For stage IA with no myometrial invasion, observation or chemotherapy with or without vaginal brachytherapy or tumor-directed radiation therapy (RT) is recommended, while for stage IA with myometrial invasion, chemotherapy with or without tumor-directed RT is suggested 1.
  • For stages IB, II, III, and IV, chemotherapy is the primary treatment, with the specific regimen depending on the stage and extent of disease 1.

Diagnostic Workup

  • The guidelines recommend biopsy for diagnosis, with optional CA-125 testing, and imaging studies such as MRI, CT, or PET as clinically indicated 1.
  • Surgical staging, similar to that for ovarian cancer, is also recommended, including TH/BSO and assessment of lymph nodes and peritoneal surfaces 1.

Treatment Approach

  • The treatment approach for serous carcinoma in the female pelvis is based on the stage and extent of disease, with a focus on comprehensive surgical staging and chemotherapy as the primary treatment modalities 1.
  • The guidelines emphasize the importance of multidisciplinary expertise and individualized treatment planning to optimize outcomes for patients with this aggressive and high-risk malignancy 1.

From the Research

NCCN Guidelines for Serous Carcinoma in Female Pelvis

  • The NCCN guidelines for serous carcinoma in the female pelvis recommend comprehensive surgical staging, including total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and peritoneal biopsies 2.
  • Adjuvant chemotherapy with platinum/taxane-based regimens is recommended for patients with high-grade serous carcinoma, with or without radiotherapy 3, 4.
  • Optimal cytoreduction and adjuvant chemotherapy appear to improve survival in patients with uterine papillary serous carcinoma (UPSC) 3, 4.
  • Therapeutic pelvic lymphadenectomy is a viable option for patients with stage I endometrial adenocarcinoma, with favorable outcomes in terms of survival and morbidity 5.

Surgical Management

  • Comprehensive surgical staging is essential for accurate diagnosis and treatment of serous carcinoma in the female pelvis 2, 3, 4.
  • Total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy are recommended as part of the surgical management 2, 5.
  • Omentectomy and peritoneal biopsies should also be performed to rule out metastatic disease 2, 3, 4.

Adjuvant Therapy

  • Platinum/taxane-based chemotherapy is recommended as adjuvant therapy for patients with high-grade serous carcinoma 3, 4.
  • Radiotherapy may be considered for patients with high-risk features or residual disease 3, 4.
  • Bevacizumab maintenance monotherapy and olaparib maintenance monotherapy may be considered for patients with recurrent or persistent disease 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.